Method of expressing human lysosomal protein in brain cells
View Patent ↗The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.
1. A method of expressing CLN2 polypeptide in brain cells of a mammalian host in need thereof comprising intracranially administering a recombinant adeno-associated viral (AAV) vector comprising a nucleic acid sequence encoding the CLN2 polypeptide as set forth in SEQ ID NO: 3, into said host under conditions that provide for expression of the CLN2 polypeptide.
2. The method of claim 1 , wherein the mammalian host is a mouse.
3. The method of claim 1 , wherein the mammalian host is a human.
4. The method of claim 1 , wherein the administration of the AAV vector increases the level of CLN2 polypeptide in the brain cells of the mammalian host.